BiPar At The Center Of Sanofi's Efforts To Rebuild Its Oncology Business
Phase III PARP inhibitor for triple-negative breast cancer leads Sanofi's efforts to restock its oncology pipeline.
Phase III PARP inhibitor for triple-negative breast cancer leads Sanofi's efforts to restock its oncology pipeline.